Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252174 | 0.88 | GSK3B (0.44) | CNR1CNR2SERPINE1MALT1 | |
| SCHEMBL5252558 | 0.86 | SLC6A3 (0.58) | CNR1CNR2SLC6A4SLC6A3MALT1 | |
| SCHEMBL1404554 | 0.86 | CHRNA7 (0.45) | CNR1CNR2SERPINE1SLC6A4SLC6A3 | |
| SCHEMBL1404667 | 0.84 | KMT2A (0.39) | CNR1CNR2SERPINE1KMT2ARXFP1 | |
| SCHEMBL5358142 | 0.76 | SRD5A2 (0.49) | CNR1 | |
| SCHEMBL1404528 | 0.76 | KDM4E (0.51) | CNR1CNR2 | |
| SCHEMBL1404527 | 0.76 | CNR1 (0.44) | CNR1CNR2SERPINE1MALT1TNKS2 | |
| SCHEMBL5355715 | 0.76 | MAPK14 (0.50) | SERPINE1KMT2AMALT1RXFP1 | |
| SCHEMBL5358072 | 0.75 | CNR1 (0.50) | CNR1CNR2SLC6A4SLC6A3CHEK1 | |
| SCHEMBL5373926 | 0.74 | MALT1 (0.53) | CNR1SERPINE1MALT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999107-B2 | Psychological disorders; cognition activators; Alzheimer's disease; headaches; nervous system antiinflammatory agents; antiepileptic agents; Parkinson's disease; Huntington's disease; schizophrenia; eating disorders | MERCK SHARP & DOHME CORP. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2109615-B1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| WO-2008094473-A1 | SUBSTITUTED PYRANO[2,3-B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| EP-1558252-B1 | SUBSTITUTED FURO [2,3-B]PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-7091216-B2 | Substituted furo[2,3-b]pyridine derivatives | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1558252-A4 | SUBSTITUTED FURO 2,3-B| PYRIDINE DERIVATIVES | MERCK & CO INC (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | MERCK SHARP & DOHME CORP. | 2005-12-08 | — | — | US | disclosed |
| EP-1558252-A2 | SUBSTITUTED FURO 2,3-B] PYRIDINE DERIVATIVES | Merck & Co., Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| WO-2004012671-A2 | SUBSTITUTED FURO [2,3-B] PYRIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272763-A1 | Substituted furo[2,3-b]pyridine derivatives | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885SERPINE1 1156/4885 |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885SERPINE1 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.